InDex Pharmaceuticals Holding AB (1NP1) Stock Statistics & Valuation Metrics

InDex Pharmaceuticals Holding AB has a market cap or net worth of €170.25M. The enterprise value is €1.53K.

InDex Pharmaceuticals Holding AB has 86,697,700 shares outstanding. The number of shares has decreased by -2.65% in one year.

InDex Pharmaceuticals Holding AB’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -23.08%.

The current PE Ratio of InDex Pharmaceuticals Holding AB is ―. InDex Pharmaceuticals Holding AB’s PEG ratio is -0.02.

In the last 12 months, InDex Pharmaceuticals Holding AB had revenue of 8.80M and earned -756.90M in profits. Earnings per share was -9.71.

In the last 12 months, operating cash flow was -37.50M and capital expenditures 3.30M, giving a free cash flow of -37.50M billion.

InDex Pharmaceuticals Holding AB pays an annual dividend of ―, resulting in a dividend yield of ―

InDex Pharmaceuticals Holding AB upcoming earnings date is Oct 15, 2026, TBA (Confirmed).

InDex Pharmaceuticals Holding AB as a current ratio of 52.31, with Debt / Equity ratio of 0.05%

In the past 12 months, InDex Pharmaceuticals Holding AB has paid -1.00M in taxes.

InDex Pharmaceuticals Holding AB EV to EBITDA ratio is -2.71, with an EV/FCF ratio of -71.76.

InDex Pharmaceuticals Holding AB has €305.70M in cash and marketable securities with €1.70M in debt, giving a net cash position of €304.00M billion.

Gross margin is 201.43%, with operating margin of -8887.50%, and net profit margin of -8601.14%.

The average price target for InDex Pharmaceuticals Holding AB is ―, which is 11.43% higher than the current price. The consensus rating is ―